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25.
Evaluation and Comparison of a Radiative Energy Attenuation Method for Determining Cholesterol in Serum
We evaluated this new technique and compared its restilts with those obtained by two commonly used enzymic methods.
Materials and Methods
Samples
The 217 subjects consisted of 103 healthy nonhospitalized volunteers (Red Cross blood donors) and 114 hospitalized inpatients, ages 17 to 64 years. The specimens from hospitalized patients were selected without conscious bias from blood samples referred to the laboratory for cholesterol determination.
After centrifuging the blood and removing the cells, we stored the plasma or serum under refrigeration were supplied by Abbott. We also used the Abbott controls experimentally to evaluate the precision of the method. We followed the manufacturer's protocol for the REA determination of cholesterol.
Auto/b5
Cholesterol, High Performance.
We adapted the Autoflo procedure (Boehringer Mannheim, Indianapolis,
IN)
to an automated system that included an automatic pipetter-diluter, an auto-carousel, and a Stasar ifi spectrophotometer (all from Gilford Instrument Labs., Oberlin, OH). Reagents were prepared and used as specified by Boehringer Mannheim. The spectrophotometer was set at a wavelength of 500 nm, with a cuvette temperature 
Reagents
For the interference study we dissolved crystalline bilirubin (Sigma Chemical Co., St. LOUIS, MO) in 10 mmol/L Error, ERR, less than or equal to ± 0.8 for all calibrators, and Root Mean Squared Error, RMSE, less than or equal to 0.5) three curves would have required re-analysis, representing an 18.8% failure rate. We evaluated controls 37 days after initial calibration to determine curve stability. All controls yielded values within ±2 SD of the mean of controls assayed during the precision study. These evaluations indicate that the same calibration curve can be used validly for at least one month.
Precision.
We determined within-assay precision by ana- 
Control material n Mean
Within-assay Abbott "low"
Abbott "medium"
Abbott "high" Between-assay Abbott "low"
Abbott"high"
DadeLevelI Dade Level II
Interference studies. We evaluated the influence of bilirubin on the REA cholesterol assay by first analyzing pa- 
Discussion
The availability of a totally automated cholesterol method is valuable in the measurement of this important and commonly measured lipid. The REA method gives accurate and reproducible results, requires a relatively short analysis time, reagent shelf.life is long, and the calibration is stable. The TDx analyzer offers reliability, rapid sample throughput, and ease of instrument operation and maintenance.
Interference from bilirubin with enzymic techniques for SD CV,% cholesterol in serum or plasma is well documented (16-18) , even though the mechanism of this interference is not well understood. Because the TDx takes a blank reading, it is 1.4 unlikely that bilirubin absorbance is the cause of this however, in our study of supplemented samples for interference we only examined the interference that would result due to the unconjugated fraction, so we cannot comment on any interference produced by conjugated biirubin. Nonetheless, bilirubin interference is well known in the clinical laboratory, many current cholesterol methods suffer from the same interference, and the percentage of highbilirubin specimens in our chemistry laboratory is low, so we believe this interference poses no substantial problems.
According to the manufacturer, negative interference in the REA assay can also be expected from therapeutic concentrations of levodopa, a dopamine precursor used in relieving symptoms of Parkinson's disease, and methyldopa, an antihypertensive medication.
A calibration curve failure rate-that is, the proportion of curves failing to meet Abbott's specifications for curve acceptance.-of 19% was cause for concern because of the potential reagent costs associated with recalibration.
The reason for this high failure rate appears to be related to the narrow acceptance/rejection criteria used by Abbott: Percent Fluorescence Intensity Error (ERR) less than or equal to ± 0.8 for all calibrators.
In our experience, an acceptance guideline for ERR of ± 1.0 yielded no clinically significant differences (± 0.07 g/L) in measured cholesterol. With this guideline, only one of the calibration curves established during the reproducibility study would have been unacceptable. Even so, by using the Abbott calibration curve acceptance criteria, combined with the documented curve stability, the 19% failure rate would result in less than two additional recalibrations per year of operation.
We conclude from our evaluation of the REA cholesterol assay that the method yields accurate and reproducible results that compare well with those obtained with other commonly used methods for cholesterol in serum and plasma.
